Alkermes Past Earnings Performance
Past criteria checks 3/6
Alkermes has been growing earnings at an average annual rate of 51.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 5.9% per year. Alkermes's return on equity is 43.2%, and it has net margins of 31.2%.
Key information
51.8%
Earnings growth rate
51.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 5.9% |
| Return on equity | 43.2% |
| Net Margin | 31.2% |
| Next Earnings Update | 01 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alkermes makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,663 | 519 | 701 | 254 |
| 30 Sep 23 | 1,591 | 215 | 723 | 374 |
| 30 Jun 23 | 1,462 | 103 | 708 | 381 |
| 31 Mar 23 | 1,121 | -164 | 653 | 374 |
| 31 Dec 22 | 1,112 | -33 | 603 | 260 |
| 30 Sep 22 | 1,132 | -129 | 627 | 370 |
| 30 Jun 22 | 1,173 | -94 | 610 | 387 |
| 31 Mar 22 | 1,201 | -62 | 600 | 391 |
| 31 Dec 21 | 1,174 | 76 | 550 | 291 |
| 30 Sep 21 | 1,129 | -92 | 566 | 401 |
| 30 Jun 21 | 1,100 | -63 | 558 | 376 |
| 31 Mar 21 | 1,044 | -95 | 551 | 373 |
| 31 Dec 20 | 1,039 | -111 | 539 | 395 |
| 30 Sep 20 | 1,171 | -74 | 566 | 462 |
| 30 Jun 20 | 1,162 | -126 | 585 | 477 |
| 31 Mar 20 | 1,194 | -139 | 606 | 489 |
| 31 Dec 19 | 1,171 | -197 | 599 | 513 |
| 30 Sep 19 | 1,074 | -201 | 598 | 412 |
| 30 Jun 19 | 1,067 | -183 | 578 | 406 |
| 31 Mar 19 | 1,092 | -173 | 561 | 409 |
| 31 Dec 18 | 1,094 | -139 | 537 | 415 |
| 30 Sep 18 | 1,054 | -139 | 507 | 410 |
| 30 Jun 18 | 1,023 | -141 | 477 | 414 |
| 31 Mar 18 | 937 | -152 | 448 | 406 |
| 31 Dec 17 | 903 | -158 | 422 | 413 |
| 30 Sep 17 | 842 | -169 | 417 | 389 |
| 30 Jun 17 | 804 | -196 | 408 | 384 |
| 31 Mar 17 | 781 | -200 | 395 | 382 |
| 31 Dec 16 | 746 | -208 | 383 | 378 |
| 30 Sep 16 | 695 | -257 | 373 | 382 |
| 30 Jun 16 | 668 | -275 | 372 | 376 |
| 31 Mar 16 | 624 | -274 | 347 | 367 |
| 31 Dec 15 | 628 | -227 | 320 | 336 |
| 30 Sep 15 | 640 | -127 | 287 | 317 |
| 30 Jun 15 | 648 | -86 | 249 | 303 |
| 31 Mar 15 | 650 | -36 | 228 | 283 |
| 31 Dec 14 | 619 | -30 | 207 | 265 |
| 30 Sep 14 | 598 | -42 | 201 | 235 |
| 30 Jun 14 | 578 | -10 | 189 | 202 |
| 31 Mar 14 | 563 | -7 | 168 | 172 |
| 31 Dec 13 | 596 | 21 | 162 | 153 |
| 30 Sep 13 | 578 | 19 | 144 | 140 |
| 30 Jun 13 | 562 | 10 | 135 | 130 |
Quality Earnings: 8AK has a high level of non-cash earnings.
Growing Profit Margin: 8AK became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8AK has become profitable over the past 5 years, growing earnings by 51.8% per year.
Accelerating Growth: 8AK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 8AK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 8AK's Return on Equity (43.2%) is considered outstanding.